Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.42 |
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 4/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | LYN | P07948 | 2/20 | 0.37 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.36 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030932 | 0.93 | PARP1 (0.47) | PARP1LRRK2QPCTQPCTLSRC | |
| SCHEMBL4030070 | 0.80 | PARP1 (0.45) | PARP1LRRK2SRCJAK2HTR4 | |
| SCHEMBL4033839 | 0.79 | EGFR (0.49) | LRRK2SRCSYKEGFRPDE4B | |
| SCHEMBL4027494 | 0.78 | PARP1 (0.48) | PARP1LRRK2SRCSMN1; SMN2EGFR | |
| SCHEMBL4032074 | 0.78 | IP6K1 (0.47) | LRRK2SRCNTRK1NTRK3NTRK2 | |
| SCHEMBL13606771 | 0.78 | PIK3CD (0.44) | LRRK2SRCSYKNTRK1NTRK3 | |
| SCHEMBL4535771 | 0.78 | PIK3CD (0.44) | LRRK2SRCSYKNTRK1NTRK3 | |
| SCHEMBL4535757 | 0.78 | PIK3CD (0.44) | LRRK2SRCSYKNTRK1NTRK3 | |
| SCHEMBL5803519 | 0.75 | DCPS (0.40) | LRRK2QPCTQPCTLSRCHTR4 | |
| SCHEMBL6675516 | 0.75 | PARP1 (0.40) | PARP1LRRK2SYKJAK2LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444210-B1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-12 | — | — | US | disclosed |
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
| EP-1444210-A1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040108-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | PARP1 895/4885LRRK2 1083/4885QPCT 54/4885 |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | PARP1 1062/4885LRRK2 1054/4885QPCT 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.